Treatment challenges in axial spondylarthritis and future directions.

about

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

P2860

Q36008355-B718BF3F-AF79-4925-B6BE-C217306D769F Q47260079-FB3E0F61-A69D-4788-80D9-ABF051CD83DF

P2860

Treatment challenges in axial spondylarthritis and future directions.

Item

http://www.wikidata.org/entity/Q38124281

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treatment challenges in axial spondylarthritis and future directions.

@en

type

Item

label

Treatment challenges in axial spondylarthritis and future directions.

@en

prefLabel

Treatment challenges in axial spondylarthritis and future directions.

@en

P1476

Treatment challenges in axial spondylarthritis and future directions.

@en

P2093

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

P2888

s11926-013-0356-9

P304

356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-013-0356-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030378474

http://www.w3.org/2001/XMLSchema#string

P698

23888365

http://www.w3.org/2001/XMLSchema#string

Treatment challenges in axial spondylarthritis and future directions.

about

P2860

P2860

Treatment challenges in axial spondylarthritis and future directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698